Research programme: cancer therapeutics - Redx Pharma

Drug Profile

Research programme: cancer therapeutics - Redx Pharma

Alternative Names: Bruton's tyrosine kinase inhibitor - Redx Pharma; Indoleamine-2,3-dioxygenase inhibitor - Redx Pharma; porcupine inhibitor - Redx Pharma; REDX 05358; REDX 08608; RXC-004; Smoothened inhibitor - Redx Pharma; T-cell target agonists - Redx Pharma

Latest Information Update: 09 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Redx Pharma
  • Developer Horizon Discovery; Redx Pharma
  • Class Small molecules
  • Mechanism of Action Raf kinase inhibitors; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Basal cell cancer
  • Research Colorectal cancer

Most Recent Events

  • 02 Jun 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Redx Pharma plans a phase I trial for Cancer in 2017
  • 03 Dec 2016 Pharmacokinetics data from a preclinical study in Cancer presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top